

vancing Biomedical Science Through Tissue

# **Cat No:** BRC964 – Breast cancer without ER, PR, HER2 expression (triple negative)

t#	Cores	Size	Cut	Format	QA/QC	j 1 2 3 4 5 6 7 8 9 10 11 12
RC96401	96	1.5mm	4um	8X12	H&E, IHC anti- Cytokeratin	Pantomics, In

**Recommended applications:** For research use only. Designed for IHC or ISH based protein or RNA tissue profiling in ER, PR, HER2 triple negative breast cancers.; Antibody characterization.

**Description:** Breast cancer tissue array without expressions of ER, PR, HER2 (triple negative), set 1, 96 cores, 48 cases containing at least five control cases with various levels of ER, PR, HER2, and 43 cases with no detectable expressions of these three markers. Since all the triple negative cases were selected out based on TMA screening, the IHC results only reflect the phenotypic status of individual cores tested at certain cutting level. We cannot exclude the possibility that, at a late cutting level, a small fraction of the cores may be positive for one or more of these three markers.

All the tissues were from surgical resection. They were fixed in 10% neutral buffered formalin for 24 hours and processed using identical SOPs. Sections were picked onto Superfrost Plus or APES coated Superfrost slides. They can be stored for use at 4C for up to six months from the date of shipment. There may be 5 to 10% of tissue core loss.

Array Position	Sex	Age	Anatomic Site	Pathology	Grade	Stage
A01	F	75	Breast	Invasive ductal carcinoma	III	null
A02	F	30	Breast	Invasive ductal carcinoma	Ι	null
A03	F	32	Breast	Invasive ductal carcinoma	III	null
A04	F	29	Breast	Invasive ductal carcinoma	III	null
A05	F	35	Breast	Invasive ductal carcinoma	II	null
A06	F	67	Breast	Invasive lobular carcinoma	II~III	null
A07	F	34	Breast	Invasive ductal carcinoma	III	null
A08	F	54	Breast	Invasive ductal carcinoma	II	null
A09	F	52	Breast	Invasive ductal carcinoma	II	null
A10	F	47	Breast	Invasive ductal carcinoma	II~III	null
A11	F	48	Breast	Invasive ductal carcinoma	II	null
A12	F	40	Breast	Invasive lobular carcinoma	II~III	null
B01	F	75	Breast	Invasive ductal carcinoma	III	null
B02	F	30	Breast	Invasive ductal carcinoma	Ι	null
B03	F	32	Breast	Invasive ductal carcinoma	III	null
B04	F	29	Breast	Invasive ductal carcinoma	III	null
B05	F	35	Breast	Invasive ductal carcinoma	II	null
B06	F	67	Breast	Invasive lobular carcinoma	II~III	null
B07	F	34	Breast	Invasive ductal carcinoma	III	null
B08	F	54	Breast	Invasive ductal carcinoma	II	null
B09	F	52	Breast	Invasive ductal carcinoma	II	null
B10	F	47	Breast	Invasive ductal carcinoma	II~III	null
B11	F	48	Breast	Invasive ductal carcinoma	II	null
B12	F	40	Breast	Invasive lobular carcinoma	II~III	null
C01	F	38	Breast	Invasive ductal carcinoma	Ι	T2N0M0
C02	F	79	Breast	Invasive ductal carcinoma	II	T2N1M0
C03	F	57	Breast	Invasive ductal carcinoma	II	T2N1M0
C04	F	43	Breast	Invasive ductal carcinoma	null	T2N0M0



#### Phone: 415-863-2380 Support: <u>info@pantomics.com</u> Web: www.pantomics.com

		Advancir	g Biomedical So	ience Through Tissue An	1 <b>6/V1</b>	
C05	F	43	Breast	Invasive ductal carcinoma	III	T3N0M0
C06	F	50	Breast	Invasive ductal carcinoma	III	T2N1M0
C07	F	40	Breast	Invasive ductal carcinoma	null	T2N1M0
C08	F	30	Breast	Invasive ductal carcinoma	II	T2N1M0
C09	F	72	Breast	Invasive ductal carcinoma	I~II	T2N1M0
C10	F	44	Breast	Invasive ductal carcinoma	null	T2N1M0
C11	F	30	Breast	Invasive ductal carcinoma	III	T2N0M0
C12	F	44	Breast	Invasive ductal carcinoma	I	T2N0M0
D01	F	38	Breast	Invasive ductal carcinoma	I	T2N0M0
D02	F	79	Breast	Invasive ductal carcinoma	II	T2N1M0
D03	F	57	Breast	Invasive ductal carcinoma	II	T2N1M0
D04	F	43	Breast	Invasive ductal carcinoma	null	T2N0M0
D05	F	43	Breast	Invasive ductal carcinoma	III	T3N0M0
D06	F	50	Breast	Invasive ductal carcinoma	III	T2N1M0
D07	F	40	Breast	Invasive ductal carcinoma	null	T2N1M0
D08	F	30	Breast	Invasive ductal carcinoma	II	T2N1M0
D09	F	72	Breast	Invasive ductal carcinoma	I~II	T2N1M0
D10	F	44	Breast	Invasive ductal carcinoma	null	T2N1M0
D10	F	30	Breast	Invasive ductal carcinoma	III	T2N0M0
D11 D12	F	44	Breast	Invasive ductal carcinoma	I	T2N0M0
E01	F	37	Breast	Invasive ductal carcinoma	II	T4N1M0
E02	F	49	Breast	Invasive ductal carcinoma	II~III	T2N0M0
E03	F	79	Breast	Invasive ductal carcinoma	II	T2N0M0
E04	F	45	Breast	Invasive ductal carcinoma	II~III	T2N0M0
E05	F	46	Breast	Invasive ductal carcinoma	III	T2N0M0
E06	F	34	Breast	Invasive lobular carcinoma	III	T2N1M0
E07	F	40	Breast	Invasive lobular carcinoma	III	T2N0M0
E08	F	64	Breast	Invasive ductal carcinoma	III	T2N1M0
E09	F	36	Breast	Invasive ductal carcinoma	III	T2N1M0
E10	F	59	Breast	Invasive ductal carcinoma	III	T2N0M0
E11	F	50	Breast	Invasive lobular carcinoma	II	T2N0M0
E12	F	36	Breast	Invasive ductal carcinoma	III	T2N0M0
F01	F	37	Breast	Invasive ductal carcinoma	II	T4N1M0
F02	F	49	Breast	Invasive ductal carcinoma	II~III	T2N0M0
F03	F	79	Breast	Invasive ductal carcinoma	II	T2N0M0
F04	F	45	Breast	Invasive ductal carcinoma	II~III	T2N0M0
F05	F	46	Breast	Invasive ductal carcinoma	III	T2N0M0
F06	F	34	Breast	Invasive lobular carcinoma	II	T2N1M0
F07	F	40	Breast	Invasive ductal carcinoma	III	T2N0M0
F08	F	64	Breast	Invasive ductal carcinoma	II	T2N1M0
F09	F	36	Breast	Invasive ductal carcinoma	III	T2N1M0
F10	F	59	Breast	Invasive ductal carcinoma	II	T2N0M0
F11	F	50	Breast	Invasive lobular carcinoma	II	T2N0M0
F12	F	36	Breast	Invasive ductal carcinoma	III	T2N0M0
G01	F	38	Breast	Invasive ductal carcinoma	II	T2N1M0
G02	F	35	Breast	Invasive ductal carcinoma	III	T2N0M0
G03	F	30	Breast	Invasive ductal carcinoma	II	T2N0M0
G04	F	34	Breast	Invasive ductal carcinoma	II	T2N1M0
G05	F	29	Breast	Invasive ductal carcinoma	II	T3N0M0
G06	F	57	Breast	Invasive ductal carcinoma	III	T2N0M0
G07	F	39	Breast	Invasive ductal carcinoma	III	T2N0M0
G08	F	41	Breast	Invasive ductal carcinoma	II	T2N2M0
G09	F	38	Breast	Invasive ductal carcinoma	III	T2N0M0
G10	F	65	Breast	Invasive ductal carcinoma	III	T2N0M0
G11	F	36	Breast	Invasive lobular carcinoma	II	T3N0M0
G12	F	34	Breast	Invasive ductal carcinoma	II	T2N0M0
~	L .		2.000			



## Phone: 415-863-2380 Support: <u>info@pantomics.com</u> Web: www.pantomics.com

		Advand	ing Biomedi	cal Science Through Tissue Ar	тауя	
H01	F	38	Breast	Invasive ductal carcinoma	II	T2N1M0
H02	F	35	Breast	Invasive ductal carcinoma	III	T2N0M0
H03	F	30	Breast	Invasive ductal carcinoma	II	T2N0M0
H04	F	34	Breast	Invasive ductal carcinoma	II	T2N1M0
H05	F	29	Breast	Invasive ductal carcinoma	II	T3N0M0
H06	F	57	Breast	Invasive ductal carcinoma	III	T2N0M0
H07	F	39	Breast	Invasive ductal carcinoma	III	T2N0M0
H08	F	41	Breast	Invasive ductal carcinoma	II	T2N2M0
H09	F	38	Breast	Invasive ductal carcinoma	III	T2N0M0
H10	F	65	Breast	Invasive ductal carcinoma	III	T2N0M0
H11	F	36	Breast	Invasive lobular carcinoma	II	T3N0M0
H12	F	34	Breast	Invasive ductal carcinoma	II	T2N0M0

**Notes:** Bake at 60C for ~60 minutes before use. If antigen retrieving is needed, it is important to avoid **direct-boiling and high pH or high strength** antigen retrieving buffer. For availability of complimentary IHC data, please contact us at info@pantomics.com.

# Certified by: Fancai Li, M.D.

## **TNM Classification: Breast carcinoma**

#### **T- Primary tumor**

- TX Primary tumor cannot be assessed
- TO No evidence of primary tumor
- Tis Carcinoma in situ, intraductal carcinoma or lobular carcinoma in situ, or Paget's disease of the nipple with no tumor
- T1 Tumor 2 cm or less in greatest dimension
- T2 Tumor more than 2 cm but not more than 5 cm in greatest dimension
- T3 Tumor more than 5 cm in greasiest dimension
- T4 Tumor of any size with direct extension to chest wall or skin

## N - Regional lymph nodes

- NX Regional lymph nodes cannot be assessed
- NO No regional lymph node metastasis
- N1 Metastasis to movable ipsilateral lymph node(s)
- N2 Metastasis to ipsilateral lymph nodes(s) fixed to one another or to other structure
- N3 Metastasis to ipsilateral internal mammary lymph node(s)

#### M - Distant metastasis

- MX Distant metastasis cannot be assessed
- MO No distant metastasis
- M1 Distant metastasis

TNM classification of malignant tumours, Fifth Edition (1997)